Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

US Oncology

Neither a doctor nor a teaching hospital

Research payments

$6,170,866

590 payments

Through program year 2025, US Oncology is reported as receiving $6,170,866 in research payments, across 590 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $89,174 7
2024 Research $582,641 16
2023 Research $965,531 191
2022 Research $1,057,599 122
2021 Research $23,868 5
2020 Research $632,247 50
2019 Research $2,819,807 199

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $2,900,339 215 payments
  2. E.R. Squibb & Sons, L.L.C. $1,307,724 104 payments
  3. Karyopharm Therapeutics Inc. $930,011 228 payments
  4. Pharmacyclics LLC, An AbbVie Company $468,804 8 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $264,959 12 payments
  6. TESARO, Inc. $241,977 5 payments
  7. Incyte Corporation $36,905 9 payments
  8. Novartis Pharmaceuticals Corporation $20,147 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Openlabel Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab in Combination With Chemotherapy Followed By Maintenance Therapy of Avelumab in Combination With the Poly Adenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Previously Untreated Advanced Ovarian Cancer Javelin Ovarian Parp100 $2,900,339 215 payments
  2. Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer $528,653 22 payments
  3. PhII MORAb-202 in 2L/3L mNSCLC - A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therap $454,204 9 payments
  4. A phase 2 open-label multicenter study to evaluate the safety and efficacy of selinexor + pembrolizumab in recurrent advanced melanoma $408,035 117 payments
  5. Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer $294,851 5 payments
  6. Combo with PD-1 inhibitor $264,959 12 payments
  7. A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer $241,977 5 payments
  8. A phase 2, randomized, open-label, multicenter study of Selinexor or Physicians choice in patients with myelofibrosis $211,901 55 payments
  9. A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma $204,900 13 payments
  10. Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer $173,954 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record